Host persistence: Exploitation of anti-inflammatory pathways by Toxoplasma gondii

Nature Reviews Immunology

Volumn 5, Issue 2, 2005, Pages 162-170

  Aliberti, Julio ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ICOSANOID; INTERLEUKIN 10; INTERLEUKIN 12; LEUKOTRIENE A4; LIPOXIN; LIPOXYGENASE;

CELLULAR IMMUNITY; CHRONIC DISEASE; CYTOKINE PRODUCTION; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFECTION CONTROL; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; HOST-PARASITE RELATIONS; HUMANS; INFLAMMATION; LIPOXINS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 13444269105     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1547     Document Type: Review

References (57)

1. Morisaki, J. H., Heuser, J. E. & Sibley, L. D. Invasion of Toxoplasma gondii occurs by active penetration of the host cell. J. Cell Sci. 108, 2457-2464 (1995). An important review of T. gondii invasion mechanisms.
2. Black, M. W. & Boothroyd, J. C. Lytic cycle of Toxoplasma gondii. Microbiol. Mol. Biol. Rev. 64, 607-623 (2000).
3. Martinez, A. J. et al. The neuropathobgy and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol. Res. Pract. 191, 427-443 (1995).
4. Hay, J. & Hutchison, W. M. Toxoplasma gondii - an environmental contaminant. Ecol. Dis. 2, 33-43 (1983).
5. Hunter, C. A., Subauste, C. S., Van Cleave, V. H. & Remington, J. S. Production of γ interferon by natural killer cells from Toxoplasma gonodii-infected SCID mice: regulation by interteukin-10, interteukin-12, and tumor necrosis factor α. Infect. Immun. 62, 2818-2824 (1994).
6. Sher, A., Oswald, I. P., Hieny, S. & Gazzinelli, R. T. Toxoplasma gondii induces a T-independent IFN-γ response in natural killer cells that requires both adherent accessory cells and tumor necrosis factor-α. J. Immunol. 150, 3982-3989 (1993).
7. Gazzinelli, R. T. et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153, 2533-2543 (1994).
8. Denkers, E. Y. From cells to signaling cascades: manipulation of innate immunity by Toxoplasma gondii. FEMS Immunol. Med. Microbiol. 39, 193-203 (2003). An up-to-date review of signalling cascades that are triggered by T. gondii.
9. Reis e Sousa, C. et al. In vivo microbial stimulation induces rapid CD40 ligand-independent traduction of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186, 1819-1829 (1997).
10. + dendritic cells. Nature Immunol. 1, 83-87 (2000).
11. Aliberti, J. et al. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nature Immunol. 4, 485-490 (2003). Identification of a CCR5 ligand mimic from T. gondii that activates IL-12 production by DCs.
12. Golding, H. et al. Inhibition of HIV-1 Infection by a CCR5-binding cyclophilin from Toxoplasma gondii. Blood 102, 3280-3286 (2003).
13. Yarovinsky, F. et al. Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. J. Biol. Chem. 279, 53635-53642 (2004).
14. Scanga, C. A. et al. MyD88 Is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 168, 5997-6001 (2002).
15. Scharton-Kersten, T., Contursi, C., Masumi, A., Sher, A. & Ozato, K. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186, 1523-1534 (1997).
16. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3, 133-146 (2003). An up-to-date review of IL-12 biology.
17. Mason, N. J. et al. TRAF6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasrna gondii. Infect. Immun. 72, 5662-5667 (2004).
18. Tsujimura, H. et al. ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 101, 961-969 (2003).
19. Yap, G. S. & Sher, A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 201, 240-247 (1999).
20. Karp, C. L. & Wills-Karp, M. Complement and IL-12: yin and yang. Mcrobes Infect. 3, 109-119 (2001).
21. Son, E. S., Song, K. J., Shin, J. C. & Nam, H. W. Molecular cloning and characterization of peroxiredoxin from Toxoplasma gondii. Korean J. Parasitol. 39, 133-141 (2001).
22. Salek-Ardakanl, S., Arrand, J. R. & Mackett, M. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on numan monocytes: implications for immune evasion by EBV. Virology 304, 342-351 (2002).
23. H1 cells. J. Immunol. 146, 3444-3451 (1991).
24. Haig, D. M. Poxvirus interference with the host cytokine response. Vet. Immunol. Immunopathol. 63, 149-156 (1998).
25. van de Loo, F. A. & van den Berg, W. B. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on inferleukin-4, interteukin-10, and interieukin-1 receptor antagonist as potential disease modulators. Rheum. Dis. Clin. North Am. 28, 127-149 (2002).
26. Wille, U., Villegas, E. N., Striepen, B., Roos, D. S. & Hunter, C. A. Interieukin-10 does not contribute to the pathogenesis of a virulent strain of Toxoplasma gondii. Parasite Immunol. 23, 291-296 (2001).
27. Deckert-Schluter, M. et al., Interteukin-10 downregulates the intracerebral immune response in chronic Toxoplasma encephalitis. J. Neuroimmunol. 76, 167-176 (1997).
28. Suzuki, Y. et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J. Immunol. 164, 5375-5382 (2000).
29. + T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol. 157, 798-805 (1996).
30. Reis e Sousa, C. et al. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity 11, 637-647 (1999).
31. 4 on DC function In vivo and in vitro.
32. Kieran, N. E., Maderna, P. & Godson, C. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65, 1145-1154 (2004).
33. Samuelsson, B. Arachidonic acid metabolism: role In inflammation. Z. Rheumatol. 50 (Suppl. 1), 3-6 (1991).
34. Goh, J., Godson, C., Brady, H. R. & Macmathuna, P. Lipoxins: pro-resolution lipid mediators in intestinal inflammation. Gastroenterology 124, 1043-1054 (2003).
35. Van Dyke, T. E. & Serhan, C. N. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82, 82-90 (2003).
36. 4 block allergen-induced eosinophil trafficking. J. Immunol. 164, 2267-2271 (2000).
37. Clish, C. B. et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96, 8247-8252 (1999).
38. 4 inhibit tumor necrosis factor 1α-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189, 1923-1930 (1999).
39. 4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J. Immunol. 173, 2091-2098 (2004).
40. Ramstedt, U., Ng, J., Wigzell, H., Serhan, C. N. & Samuelsson, B. Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicrty: effects on intracellular cAMP and target cell binding. J. Immunol. 135, 3434-3438 (1985).
41. 4 receptor. J. Biol. Chem. 272, 6972-6978 (1997).
42. 4: a new class of ligand for the Ah receptor. Biochemistry 38, 7594-7600 (1999).
43. Devchand, P. R. et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J. 17, 652-659 (2003).
44. 4, is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13, 1657-1662 (2002).
45. Alexander, W. S. & Hilton, D. J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503-529 (2004).
46. Kile, B. T. et al. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27, 235-241 (2002).
47. Hong, S., Gronert, K., Devchand, P. R., Moussignac, R. L. & Serhan, C. N. Novel docosatrienes and 175-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687 (2003).
48. Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
49. 4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196, 1253-1262 (2002). An original report on the role of endogenous lipoxins in modulating pro-inflammatory responses during infection with T. gondii.
50. Funk, C. D., Chen, X. S., Johnson, E. N. & Zhao, L. Lipoxygenase genes and their targeted disruption. Prostaglaridins Other Lipid Mediat. 68-69, 303-312 (2002).
51. Goulet, J. L. et al. Deficiency of 5-lipoxygenase abolishes sex-related survival differences in MRL-lpr/lpr mice. J. Immunol. 163, 359-366 (1999).
52. 4 biosynthesis. J. Exp. Med. 199, 515-523 (2004). Identification of a lipoxygenase activity in T. gondil that has immunomodulatory effects in vivo.
53. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2, 612-619 (2001).
54. Vance, R. E., Hong, S., Gronert, K., Serhan, C. N. & Mekalanos, J. J. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc. Natl Acad. Sci. USA. 101, 2135-2139 (2004). Identification of a 15-lipoxygenase in the cystic-fibrosis-causing pathogen P. aeruginosa.
55. Karp, C. L. et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nature Immunol. 5, 388-392 (2004). Identification of a defect in the generation of lipoxin in patients with cystic fibrosis.
56. Chan, J. & Flynn, J. The immunological aspects of latency in tuberculosis. Clin. Immunol. 110, 2-12 (2004).
57. Flynn, J. L. & Chan, J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr. Opin. Immunol. 15, 450-455 (2003). An up-to-date review on the immune-evasion mechanisms of M. tuberculosis.